Symbols / NVNO Stock $10.44 -3.33% enVVeno Medical Corporation
NVNO (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Ratings
Current target
$10.44
Low
—
High
—
Mean
—
- FDA allows first U.S. study of a nonsurgical vein valve for 3M patients - Stock Titan Wed, 29 Apr 2026 12
- enVVeno Medical (NVNO) Secures FDA IDE Approval for Pivotal Stud - GuruFocus Wed, 29 Apr 2026 17
- enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement - Times Reporter Wed, 29 Apr 2026 03
- enVVeno Medical Announces Reverse Stock Split - Yahoo Finance hu, 15 Jan 2026 08
- $NVNO stock is down 40% today. Here's what we see in our data. - Quiver Quantitative Fri, 14 Nov 2025 08
- enVVeno Medical Wins FDA IDE for TAVVE Trial - TipRanks Wed, 29 Apr 2026 13
- FDA clears enVVeno (NASDAQ: NVNO) pivotal enVVe CVI valve study - Stock Titan Wed, 29 Apr 2026 12
- enVVeno Medical stock plunges after FDA upholds rejection of VenoValve - Investing.com Fri, 14 Nov 2025 08
- Insider Buyers Lose US$294k As enVVeno Medical Sheds US$1.9m - simplywall.st Sat, 22 Nov 2025 08
- NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve - Yahoo Finance Mon, 25 Aug 2025 07
- What enVVeno's 1-for-35 reverse stock split means for shareholders in 2026 - Stock Titan hu, 15 Jan 2026 08
- EnVVeno Medical shareholders approve reverse stock split, reject equity plan - Investing.com Fri, 12 Dec 2025 08
- enVVeno Medical stock plummets after FDA rejects VenoValve approval - Investing.com Wed, 20 Aug 2025 07
- Latest NVNO News - enVVeno Medical Reports Full Year 2025 Fina... - Stock Titan hu, 15 Jan 2026 08
- EnVVeno Medical receives Nasdaq notice for minimum bid price non-compliance - Investing.com Fri, 10 Oct 2025 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
20.90
-12.28%
|
23.83
-5.59%
|
25.24
+1.23%
|
24.93
|
| Research And Development |
|
9.98
-18.52%
|
12.25
-9.82%
|
13.58
+37.01%
|
9.91
|
| Selling General And Administration |
|
10.92
-5.69%
|
11.58
-0.67%
|
11.65
-22.39%
|
15.02
|
| General And Administrative Expense |
|
10.92
-5.69%
|
11.58
|
—
|
—
|
| Salaries And Wages |
|
6.15
-2.20%
|
6.29
|
—
|
—
|
| Other Gand A |
|
3.56
-11.14%
|
4.01
|
—
|
—
|
| Total Expenses |
|
20.90
-12.28%
|
23.83
-5.59%
|
25.24
+1.23%
|
24.93
|
| Operating Income |
|
-20.90
+12.28%
|
-23.83
+5.59%
|
-25.24
-1.23%
|
-24.93
|
| Total Operating Income As Reported |
|
-20.90
+12.28%
|
-23.83
+5.59%
|
-25.24
-1.23%
|
-24.93
|
| EBITDA |
|
-20.41
+12.40%
|
-23.30
+5.65%
|
-24.69
-1.17%
|
-24.41
|
| Normalized EBITDA |
|
-21.14
+15.13%
|
-24.92
+5.02%
|
-26.23
-7.04%
|
-24.51
|
| Reconciled Depreciation |
|
0.49
-7.39%
|
0.53
-3.30%
|
0.55
+4.00%
|
0.53
|
| EBIT |
|
-20.90
+12.28%
|
-23.83
+5.59%
|
-25.24
-1.23%
|
-24.93
|
| Total Unusual Items |
|
0.73
-54.57%
|
1.62
+4.93%
|
1.54
+1411.76%
|
0.10
|
| Total Unusual Items Excluding Goodwill |
|
0.73
-54.57%
|
1.62
+4.93%
|
1.54
+1411.76%
|
0.10
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-19.47
+10.76%
|
-21.82
+7.22%
|
-23.52
+4.67%
|
-24.67
|
| Pretax Income |
|
-19.47
+10.76%
|
-21.82
+7.22%
|
-23.52
+4.67%
|
-24.67
|
| Net Non Operating Interest Income Expense |
|
0.69
+77.89%
|
0.39
+116.11%
|
0.18
+11.80%
|
0.16
|
| Net Interest Income |
|
0.69
+77.89%
|
0.39
+116.11%
|
0.18
+11.80%
|
0.16
|
| Interest Income Non Operating |
|
0.69
+77.89%
|
0.39
+116.11%
|
0.18
+11.80%
|
0.16
|
| Interest Income |
|
0.69
+77.89%
|
0.39
+116.11%
|
0.18
+11.80%
|
0.16
|
| Other Income Expense |
|
0.73
-54.57%
|
1.62
+4.93%
|
1.54
+1411.76%
|
0.10
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
0.73
-54.57%
|
1.62
+4.93%
|
1.54
+1411.76%
|
0.10
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-19.47
+10.76%
|
-21.82
+7.22%
|
-23.52
+4.67%
|
-24.67
|
| Net Income From Continuing Operation Net Minority Interest |
|
-19.47
+10.76%
|
-21.82
+7.22%
|
-23.52
+4.67%
|
-24.67
|
| Net Income From Continuing And Discontinued Operation |
|
-19.47
+10.76%
|
-21.82
+7.22%
|
-23.52
+4.67%
|
-24.67
|
| Net Income Continuous Operations |
|
-19.47
+10.76%
|
-21.82
+7.22%
|
-23.52
+4.67%
|
-24.67
|
| Normalized Income |
|
-20.21
+13.78%
|
-23.44
+6.47%
|
-25.06
-1.16%
|
-24.77
|
| Net Income Common Stockholders |
|
-19.47
+10.76%
|
-21.82
+7.22%
|
-23.52
+4.67%
|
-24.67
|
| Diluted EPS |
|
-33.06
+25.76%
|
-44.53
+33.39%
|
-66.85
+13.18%
|
-77.00
|
| Basic EPS |
|
-33.06
+25.76%
|
-44.53
+33.39%
|
-66.85
+13.18%
|
-77.00
|
| Basic Average Shares |
|
0.59
+20.20%
|
0.49
+39.42%
|
0.35
+9.54%
|
0.32
|
| Diluted Average Shares |
|
0.59
+20.20%
|
0.49
+39.42%
|
0.35
+9.54%
|
0.32
|
| Diluted NI Availto Com Stockholders |
|
-19.47
+10.76%
|
-21.82
+7.22%
|
-23.52
+4.67%
|
-24.67
|
| Insurance And Claims |
|
0.61
-6.87%
|
0.66
|
—
|
—
|
| Rent And Landing Fees |
|
0.60
-4.63%
|
0.63
|
—
|
—
|
| Rent Expense Supplemental |
|
0.60
-4.63%
|
0.63
|
—
|
—
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
29.56
-34.24%
|
44.95
-7.57%
|
48.63
+16.74%
|
41.66
|
| Current Assets |
|
28.83
-34.09%
|
43.73
-6.80%
|
46.92
+18.99%
|
39.44
|
| Cash Cash Equivalents And Short Term Investments |
|
28.21
-34.62%
|
43.15
-7.02%
|
46.41
+18.87%
|
39.04
|
| Cash And Cash Equivalents |
|
3.06
+74.74%
|
1.75
-51.55%
|
3.62
-20.53%
|
4.55
|
| Cash Financial |
|
—
|
—
|
—
|
—
|
| Other Short Term Investments |
|
25.15
-39.26%
|
41.40
-3.26%
|
42.79
+24.07%
|
34.49
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
0.61
+5.68%
|
0.58
+13.70%
|
0.51
+30.36%
|
0.39
|
| Total Non Current Assets |
|
0.74
-39.67%
|
1.22
-28.74%
|
1.71
-23.06%
|
2.23
|
| Net PPE |
|
0.70
-40.71%
|
1.19
-29.27%
|
1.68
-23.38%
|
2.19
|
| Gross PPE |
|
2.10
-14.23%
|
2.45
-11.05%
|
2.75
-9.63%
|
3.04
|
| Accumulated Depreciation |
|
-1.39
-10.82%
|
-1.26
-17.59%
|
-1.07
-25.91%
|
-0.85
|
| Properties |
|
—
|
—
|
—
|
0.00
|
| Machinery Furniture Equipment |
|
0.88
+0.57%
|
0.87
+2.11%
|
0.85
+1.06%
|
0.85
|
| Other Properties |
|
1.22
-22.44%
|
1.57
-16.99%
|
1.90
-13.75%
|
2.20
|
| Leases |
|
—
|
—
|
—
|
0.21
|
| Non Current Prepaid Assets |
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
+0.00%
|
0.03
|
| Other Non Current Assets |
|
—
|
—
|
0.03
+0.00%
|
0.03
|
| Total Liabilities Net Minority Interest |
|
2.43
-12.99%
|
2.79
+14.78%
|
2.44
-16.95%
|
2.93
|
| Current Liabilities |
|
2.12
+1.29%
|
2.10
+52.81%
|
1.37
-10.39%
|
1.53
|
| Payables And Accrued Expenses |
|
0.80
-20.18%
|
1.01
+135.60%
|
0.43
-34.10%
|
0.65
|
| Payables |
|
0.36
-64.41%
|
1.01
+135.60%
|
0.43
-34.10%
|
0.65
|
| Accounts Payable |
|
0.36
-64.41%
|
1.01
+135.60%
|
0.43
-34.10%
|
0.65
|
| Current Accrued Expenses |
|
0.45
|
0.00
|
—
|
0.12
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.80
+31.62%
|
0.60
+26.36%
|
0.48
+22.25%
|
0.39
|
| Current Debt And Capital Lease Obligation |
|
0.39
+7.14%
|
0.36
+7.69%
|
0.34
+7.64%
|
0.31
|
| Current Capital Lease Obligation |
|
0.39
+7.14%
|
0.36
+7.69%
|
0.34
+7.64%
|
0.31
|
| Other Current Liabilities |
|
0.13
+10.74%
|
0.12
-5.47%
|
0.13
-27.68%
|
0.18
|
| Total Non Current Liabilities Net Minority Interest |
|
0.31
-55.71%
|
0.70
-34.21%
|
1.06
-24.11%
|
1.40
|
| Long Term Debt And Capital Lease Obligation |
|
0.31
-55.71%
|
0.70
-34.21%
|
1.06
-24.11%
|
1.40
|
| Long Term Capital Lease Obligation |
|
0.31
-55.71%
|
0.70
-34.21%
|
1.06
-24.11%
|
1.40
|
| Stockholders Equity |
|
27.13
-35.65%
|
42.16
-8.75%
|
46.20
+19.29%
|
38.73
|
| Common Stock Equity |
|
27.13
-35.65%
|
42.16
-8.75%
|
46.20
+19.29%
|
38.73
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
0.66
+30.93%
|
0.50
+31.68%
|
0.38
+40.59%
|
0.27
|
| Ordinary Shares Number |
|
0.66
+30.93%
|
0.50
+31.68%
|
0.38
+40.59%
|
0.27
|
| Additional Paid In Capital |
|
198.46
+2.29%
|
194.01
+10.09%
|
176.24
+21.33%
|
145.25
|
| Retained Earnings |
|
-171.33
-12.82%
|
-151.85
-16.78%
|
-130.04
-22.08%
|
-106.52
|
| Total Equity Gross Minority Interest |
|
27.13
-35.65%
|
42.16
-8.75%
|
46.20
+19.29%
|
38.73
|
| Total Capitalization |
|
27.13
-35.65%
|
42.16
-8.75%
|
46.20
+19.29%
|
38.73
|
| Working Capital |
|
26.70
-35.87%
|
41.64
-8.59%
|
45.55
+20.17%
|
37.91
|
| Invested Capital |
|
27.13
-35.65%
|
42.16
-8.75%
|
46.20
+19.29%
|
38.73
|
| Total Debt |
|
0.70
-34.21%
|
1.06
-24.11%
|
1.40
-18.30%
|
1.72
|
| Capital Lease Obligations |
|
0.70
-34.21%
|
1.06
-24.11%
|
1.40
-18.30%
|
1.72
|
| Net Tangible Assets |
|
27.13
-35.65%
|
42.16
-8.75%
|
46.20
+19.29%
|
38.73
|
| Tangible Book Value |
|
27.13
-35.65%
|
42.16
-8.75%
|
46.20
+19.29%
|
38.73
|
| Current Notes Payable |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-15.57
+7.54%
|
-16.84
+10.71%
|
-18.86
-20.74%
|
-15.62
|
| Cash Flow From Continuing Operating Activities |
|
-15.57
+7.54%
|
-16.84
+10.71%
|
-18.86
-20.74%
|
-15.62
|
| Net Income From Continuing Operations |
|
-19.47
+10.76%
|
-21.82
+7.22%
|
-23.52
+4.67%
|
-24.67
|
| Depreciation Amortization Depletion |
|
0.49
-7.39%
|
0.53
-3.30%
|
0.55
+4.00%
|
0.53
|
| Depreciation |
|
0.49
-7.39%
|
0.53
-3.30%
|
0.55
+4.00%
|
0.53
|
| Depreciation And Amortization |
|
0.49
-7.39%
|
0.53
-3.30%
|
0.55
+4.00%
|
0.53
|
| Other Non Cash Items |
|
—
|
—
|
—
|
-0.29
|
| Stock Based Compensation |
|
3.42
-17.41%
|
4.14
-20.30%
|
5.20
-42.23%
|
8.99
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
0.39
+1677.27%
|
0.02
+104.70%
|
-0.47
-855.10%
|
-0.05
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
-0.40
-236.55%
|
0.29
+147.08%
|
-0.62
-46.67%
|
-0.42
|
| Change In Prepaid Assets |
|
-0.03
+52.86%
|
-0.07
+41.18%
|
-0.12
-108.77%
|
-0.06
|
| Change In Payables And Accrued Expense |
|
0.00
-99.86%
|
0.70
+481.42%
|
-0.18
-150.68%
|
-0.07
|
| Change In Accrued Expense |
|
—
|
—
|
0.04
+123.60%
|
-0.16
|
| Change In Payable |
|
—
|
—
|
-0.22
-351.14%
|
0.09
|
| Change In Account Payable |
|
—
|
—
|
-0.22
-351.14%
|
0.09
|
| Change In Other Current Liabilities |
|
-0.36
-7.69%
|
-0.34
-7.64%
|
-0.31
-8.28%
|
-0.29
|
| Investing Cash Flow |
|
15.86
+1087.72%
|
1.33
+116.97%
|
-7.87
+77.23%
|
-34.55
|
| Cash Flow From Continuing Investing Activities |
|
15.86
+1087.72%
|
1.33
+116.97%
|
-7.87
+77.23%
|
-34.55
|
| Net PPE Purchase And Sale |
|
-0.01
+86.49%
|
-0.04
-12.12%
|
-0.03
+71.30%
|
-0.12
|
| Purchase Of PPE |
|
-0.01
+86.49%
|
-0.04
-12.12%
|
-0.03
+71.30%
|
-0.12
|
| Capital Expenditure |
|
-0.01
+86.49%
|
-0.04
-12.12%
|
-0.03
+71.30%
|
-0.12
|
| Net Investment Purchase And Sale |
|
15.86
+1056.05%
|
1.37
+117.51%
|
-7.83
+77.25%
|
-34.44
|
| Purchase Of Investment |
|
-46.02
+17.18%
|
-55.57
+1.69%
|
-56.52
-17.44%
|
-48.13
|
| Sale Of Investment |
|
61.88
+8.68%
|
56.94
+16.95%
|
48.69
+255.68%
|
13.69
|
| Financing Cash Flow |
|
1.02
-92.50%
|
13.64
-47.12%
|
25.79
|
0.00
|
| Cash Flow From Continuing Financing Activities |
|
1.02
-92.50%
|
13.64
-47.12%
|
25.79
|
0.00
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
0.78
-94.25%
|
13.59
-47.30%
|
25.79
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.24
+423.91%
|
0.05
|
0.00
|
0.00
|
| Changes In Cash |
|
1.31
+170.26%
|
-1.87
-99.57%
|
-0.94
+98.14%
|
-50.17
|
| Beginning Cash Position |
|
1.75
-51.55%
|
3.62
-20.53%
|
4.55
-91.68%
|
54.73
|
| End Cash Position |
|
3.06
+74.74%
|
1.75
-51.55%
|
3.62
-20.53%
|
4.55
|
| Free Cash Flow |
|
-15.57
+7.72%
|
-16.88
+10.67%
|
-18.89
-20.06%
|
-15.73
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
0.00
|
| Common Stock Issuance |
|
0.78
-94.25%
|
13.59
-47.30%
|
25.79
|
0.00
|
| Issuance Of Capital Stock |
|
0.78
-94.25%
|
13.59
-47.30%
|
25.79
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-29 View
- 10-K2026-03-26 View
- 42026-03-13 View
- 8-K2026-02-04 View
- 8-K2026-01-20 View
- 42025-12-18 View
- 42025-12-18 View
- 42025-12-18 View
- 42025-12-15 View
- 42025-12-15 View
- 42025-12-15 View
- 42025-12-15 View
- 42025-12-12 View
- 8-K2025-12-12 View
- 8-K2025-11-20 View
- 8-K2025-11-14 View
- 8-K2025-10-30 View
- 10-Q2025-10-30 View
- 8-K2025-10-10 View
- 42025-09-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|